The effects of CIL-102 on the prostate cancer cells
碩士 === 大仁科技大學 === 製藥科技研究所 === 98 === Hormone ablation so far remains the first-line treatment of prostate cancer. Hormone ablation therapy eventually fails for the most patients due to the diseases developing into hormone-refractory state. Thus, the U.S. (United State) Food and Drug Administration (...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2010
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/67148748158849799994 |